Cardinal Aligns Manufacturing Businesses

Cardinal Health has made organizational changes to align its manufacturing businesses and sharpen its focus on expanding the market for its products and services outside the U.S.

David L. Schlotterbeck has assumed additional responsibility for Cardinal Health’s Pharmaceutical Technologies and Services (PTS) and Medical Products Manufacturing (MPM) segments, in addition to his current responsibility for the Clinical Technologies and Services (CTS) segment. As chief executive officer of Pharmaceutical and Medical Products, Mr. Schlotterbeck will lead an organization of approximately 23,000 employees and $6 billion in revenues.

According to a company statement, PTS, MPM and CTS will remain separate financial reporting segments and separate internal organizations, but the new structure will “foster a uniform approach to lean manufacturing and Six Sigma initiatives, and common processes for innovation, R&D, and sourcing.”

“Dave’s extensive manufacturing experience and more recent leadership in transforming our CTS segment make him an ideal choice for this new, important role,” said R. Kerry Clark, president and chief executive officer of Cardinal Health. “The leadership structure we now have in place across Cardinal Health will help us streamline decision making, create new and innovative solutions with more insight and speed, and enable us to accelerate the work we do to make health care safer and more productive.”

The company has also appointed R. G. G. (Rudy) Mareel as president of International. In this role, Mr. Mareel will develop and implement the company’s international strategy. He will also assume the responsibilities of John Parker, president of Cardinal Health Europe, who plans to retire.

Mr. Mareel joins the company from Royal Numico, a global clinical and specialized nutrition products co., where he was president of the Amsterdam-based clinical nutrition division and a member of its executive board. Prior to joining Royal Numico in 2001, he worked for several years at Becton Dickinson, where he served in a number of global positions, most recently as worldwide vice president and general manager of BD Biosciences, Immunocytometry Systems.